Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace
LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce Annovis Bio's (NYSE:ANVS) recent feature on Today's Marketplace (TMP) as part of its commitment to amplifying industry leaders' voices through targeted distribution channels.
The full interview can be viewed at https://ibn.fm/m7gvX.
This TMP episode highlights an exclusive interview with Dr. Maria Maccecchini, Founder, President, and CEO of Annovis Bio. Conducted by host Jane King, the discussion focused on Annovis' groundbreaking drug development for neurodegenerative diseases such as Alzheimer's and Parkinson's.
"We think of the patients, but we should also think of the caregivers because the caregivers are very much affected by neurodegeneration too," Dr. Maccecchini shared during the interview. She also elaborated on the next-phase clinical trials for Annovis' drug, which targets the toxic proteins responsible for nerve cell damage in both diseases.
TMP, filmed at prestigious venues like the New York Stock Exchange and NASDAQ MarketSite, is renowned for delivering compelling interviews with C-suite executives, targeting investors, financial professionals, and industry stakeholders. Dr. Maccecchini remarked, "It was an incredible experience to speak on TMP and share insights about our work at Annovis. I encourage viewers to tune in and explore more about the meaningful progress we're making."
To watch the full interview and gain deeper insights into Annovis Bio's innovation visit: Annovis Bio Inc. (NYSE:ANVS) Video Profile
The TMP feature continues to reinforce IBN's dedication to delivering high-value content syndication and amplifying corporate messages across financial and media networks. For more than 18 years, IBN has provided innovative branding and communication strategies to over 500 public and private companies.
About Annovis Bio Inc.
Headquartered in Malvern, Pennsylvania, Annovis Bio Inc. is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company's innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com
About IBN
IBN consists of financial brands introduced to the investment public over the course of 18+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.
Through our Dynamic Brand Portfolio (DBP), IBN provides: (1) access to a network of wire solutions via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) Press Release Enhancement to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) total news coverage solutions.
For more information, please visit https://www.InvestorBrandNetwork.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.fm/Disclaimer
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications
IBN
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]
